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Summary.-Serum lysozyme activity was measured in groups of untreated patients
with malignant melanoma, hypernephroma and breast carcinoma. Significant
elevation of serum levels of the enzyme was confined to patients with localized
disease. In the presence of metastatic disease such elevation was not detected.
The rise in serum lysozyme activity was not due to renal damage or any infective
process and in the case of malignant melanoma was shown to be associated with
infiltration of the tumour mass by macrophages. In vitro studies demonstrated
that the macrophages resident in a tumour mass are responsible for releasing
lysozyme in large amounts. It is proposed that the elevation of serum lysozyme
in these cases may be an indicator of macrophage-mediated host resistance and
that the measurement of macrophage products such as lysozyme in the extracellular
fluid may under well defined conditions provide useful clinical information concern-
ing host reactions.
IN THE serum ofrats bearing syngeneic
immunogenic tumours there are elevated
levels of lysozyme (mucopeptide n-acetyl
muramyl hydrolase EC 3.2.1.17), much
of which is released from macrophages
resident in the tumour mass and the
regional draining lymph nodes (Currie
and Eccles, 1976). In such animals the
serum lysozyme levels appear to reflect
the degree of macrophage-mediated host
resistance and correlate with several
features of the natural history of the
tumours. This brief report describes an
extension of these studies designed to
examine serum lysozyme levels in cancer
patients to determine whether an assay
for lysozyme in the serum can give
clinically relevant information about host
responses and the biological behaviour of
the tumours.
MATERIALS AND METHODS
Lysozyme assay. The lysoplate assay
described by Osserman and Lawlor (1966)
was adapted for use as previously described
(Currie and Eccles, 1976). A standardized
batch of normal human serum was used to
calibrate each lysoplate assay.
Patients 8tudied.-Serum samples were
obtained from patients with a histologically
proven diagnosis of malignant melanoma,
hypernephroma or breast carcinoma. The
sera were obtained before any treatment
was given. Patients were excluded from
the study if there was any known unrelated
gross pathology or if they were taking any
form of medication. None of the patients
showed any clinical or laboratory evidence
ofrenal malfunction and none had anyknown
infective process. The individual groups
of patients studied and the staging methods
employed will be described below. Sera
from 21 normal unmatched individuals
were also examined. Their ages ranged
from 17 to 60 years.
RESULTS
Malignant melanoma
Serum samples from 72 patients with
a histologically proven diagnosis of malig-
nant melanoma were assayed for lysozymeG. A. CURRIE
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FIG. 1. Serum lysozyme activity in 72 patients with malignant melanoma and 21 unmatched
normal controls. Patients with Stage I disease show a statistically significant elevation in mean
lysozyme level when compared to the normal controls or to those with Stage III disease.
activity. Clinically, these patients were
staged into three broad categories. Stage
I comprised those patients with an
untreated primary tumour with no evi-
dence of dissemination. The Stage II
patients had regional dissemination to
either skin or lymph nodes with no
detectable disease beyond the regional
lymph nodes. Stage III cases were those
with distant metastases to any site.
Sera from the 21 normal individuals were
also assayed for lysozyme activity. The
results are represented diagrammatically
in Fig. 1 and indicate that the Stage I
patients have elevated levels of lysozyme
when compared to the normals or to
the patients with disseminated disease
(Stage III). Using Student's " t " test
the significance of the difference between
these groups was P < 001. In other
words, elevated serum lysozyme in malig-
nant melanoma patients is associated
with localized disease. However, as can
be seen from the diagram, the difference
between the mean serum lysozyme in
the Stage I cases and either the normals
or the Stage III cases is partly due to
a small number of Stage I cases with
substantial elevation in serum lysozyme
activity. Whether or not the subgroup
has a better prognosis is the subject of
prospective studies.
Hypernephroma
In these 25 patients, marked elevation
of the serum lysozyme was found almost
exclusively in those cases with disease
confined to the kidney (see Fig. 2).
However, in one patient with a single
1 cm lung metastasis (examined 3 months
after nephrectomy) there was significant
elevation. Two patients with localized
primary tumours had abnormally low
levels of lysozyme but both these cases
had received preoperative irradiation to
the renal area. The difference between
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FIG. 2. Serum lysozyme activity in patients with hypernephroma, showing significant elevation
in those with disease confined to the kidney. Two cases, 0, had received irradiation to the
renal area before the blood samples were taken. One patient, (@*), with elevated lysozyme activity
in his serum had only a single small static metastasis in one lung.
the two groups is significant at the 500
level even when the three aberrant values
are included. The serum lysozyme levels
in the normal controls are also included
in this figure for comparison.
(Carcinoma of the breast
Sera were obtained from patients at
their first presentation at a breast clinic
and were assayed for lysozyme activity.
The patients were subsequently admitted
to hospital for investigation, staging and
treatment. Of the 97 sera tested, there
were 84 untreated cases of breast car-
cinoma and 13 with benign breast lesions.
The 84 new cases of breast cancer
were staged surgically, histologically and
by intensive investigation including bone-
marrow examinations, bone scanning,
liver scanning and ultrasonography and
a complete biochemical profile including
serum calcium, alkaline phosphatase and
urinary hydroxyproline excretion.
There were 20 cases with an isolated
primary tumour (T+, No, Mo), 30 with
histologically proven node metastases
(T+, N+, Mo) and 34 who presented
with evidence of distant metastases (T+,
N+, M+).
The serum lysozyme results are shown
in Fig. 3.
The mean serum lysozyme levels in
cases with disease confined to the breast
were significantly higher than those with
either lymph node or distant metastases
(P < 0.05) but it can be seen from the
diagram that the area of overlap was
extensive and that this difference is due
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and in those cases with axillary node
involvement there was similarly no statis-
tically significant elevation. Staging of
the tumour alone revealed an association
between tumour stage and serum lysozyme
but only in those cases free from meta-
static disease, i.e. the more extensive
the primary tumour, the higher the
serum lysozyme. This correlation was
absent in the cases with detectable nodal
or distant metastases. Examination of
those cases with disease confined to the
breast has failed to reveal any obvious
association between histological appear-
ance and the serum lysozyme.
Release of lysozyme by cells from deposits
of malianant melanoma
S Samples of tumour obtained at opera-
* tion were washed, trimmed free of normal
and necrotic areas and finely chopped
with a pair of scalpel blades. A single
cell suspension was then obtained by
I 0 ' ' ' - enzyme disaaareaation usina 01°O/,, trvpsin
BENIGN No Mo M and 0.I% collagenase. The enzyme treat-
BENIGNNo Mo ment was continued at 37TC until all
Mo macroscopic fragments had disappeared
3.-Serum lysozyme activityin patients (usually 1-1- h). The resulting cell sus-
,ith benign (13 cases) or malignant (84 pensions were washed twice in medium
ses) breast lesions. The three benign . . o Etses with the highest lysozyme levels, O, 199 containing 10% foetal bovine serum
ad inflammatory lesions, the remainder and once in serum-free medium. Finally
,ere typical cases of fibroadenosis. In the cells were resuspended in serum-free
ie carcinoma patients all those with lyso-
yme-levels above 12-5 ,ug/ml had no evid- medium at 4 X 106/ml. Twenty-ul sam-
nce ofmetastatic disease. ples of these suspensions were then
added to the wells of lysozyme assay
group of the T+, No, Mo cases with plates (containing medium 199 as the
Jted lysozyme levels. However, as buffer diluent) and were incubated for
liagram indicates, a serum lysozyme 24 h at 37TC in a 5% CO2 atmosphere.
bove 12-5 ,tg/ml in a patient with Standard curves of normal human lyso-
stologically proven primary breast zyme were obtained on the same plates
noma is associated with the absence and the results were expressed as ,ug
rert metastatic disease. The benign lysozyme/106 cells/24 h.
;t lesions seem to fall into two Cells from these suspensions were also
ps. Three cases with inflammatory cultured in RPMI1640 plus 10% foetal
ses (2 degenerating cysts and 1 case bovine serum in plastic culture flasks.
it necrosis) had abnormally high After two days' incubation the cultures
yme levels, whereas the remainder, were washed and trypsinized for 5 min
fibroadenosis, were within the normal with 0.1% trypsin. The detached cells
In untreated patients with distant were then assayed for lysozyme release
stases the lysozyme levels were not as above. Passaged tumour cells ob-
Rcantly different from the normals tained in this way failed to release
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Fie. 4.--Release oflysozyme from cell suspen-
sions fiom biopsy specimens of malignant
melanioma. The highest lysozyme levels
were foundl in localized lesions and(i this was
associated ith the preseiice ofmacrophages.
The results are expressed as ,ug lysozyme
released/106 cells/(lay.
detectable lysozyme, whereas the cells
not removed from the flasks by trypsin
(morphologically these were macrophages)
continued to release detectable lysozyme
activity into the culture supernatant for
several weeks.
Suitable suspensions of high viability
were obtained from 16 cases of malignant
melanoma. Detectable lysozyme release
was present in 13 of these and in each
the lysozyme was released from tumour
macrophages and not from the malignant
cells themselves. The data obtained from
these cases are shown diagrammatically
in Fig. 4. As this diagram shows, sub-
stantial release of lysozyme was only
detectable in samples obtained from
localized deposits, whereas the release
of lysozyme by cells from distant meta-
stases was minimal. This simple assay
procedure may give useful semi-quantita-
tive information concerning the degree
of macrophage infiltration of a tumour.
How well these in vitro results reflect
the relative proportion of macrophages in
vivo in a solid tumour mass is of course
open to question. However, the value
of lysozvme release for measuring macro-
phage contamination of a " tumour cell "
suspension in this system was confirmed
by the studies of Gauci and Alexander
(1975) who examined the same cell
suspensions for macrophage content using
a specific anti-human macrophage serum
and obtained similar results.
DISCUSSION
If the levels of lysozyme in the serum
of cancer patients are a reflection of
host resistance, as seems to be the case
in an animal model (Currie and Eccles,
1976) certain predictions can be made.
Patients with localized primary tumours
should have higher levels than both
normal individuals and those with meta-
static disease. The data obtained from
patients with malignant melanoma, hy-
pernephroma and breast carcinoma are
in accord with such a prediction.
The breast carcinoma cases were
staged surgically, histologically and by
intensive investigation, and it can be
seen that those women with a histo-
logically proven primary breast carcinoma
who presented with significant elevation
in serum lysozyme (above 12*5 /tg/ml)
had no detectable metastatic disease.
Any further conclusions about the prog-
nostic significance of such an observation
must obviously await a prospective con-
trolled study. However, it is tantalizing
to note that exactly half the patients
with a localized primary breast car-
cinoma (NoMo) show a significant eleva-
tion in serum lysozyme.
Fogelson and Lobstein (1954) have
examined the lysozyme content of whole
blood in 77 normal individuals and 35
patients with localized and generalized
carcinomatosis. They demonstrated that
the cancer patients had statistically higher
blood lysozyme activity than the normal
individuals. However, they stated that
the increase had no clinical or diagnostic
significance. In patients with malignant
tumours of the urinary tract, Kovanyi and
Letnansky (1971) have shown significant
elevation of lysozyme in both urine and
serum. They claimed that the simul-
I I I
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taneous estimation of urinary and serum
lysozyme activity was a valuable diag-
nostic test for malignant disease in the
genito-urinary tract. More recently
Cooper et al. (1974) have examined
serum lysozyme activity in patients with
colo-rectal cancer before and after surgical
treatment and indicated that patients
with primary tumours had significantly
higher serum lysozyme levels than normal
controls and that surgical excision led
to a significant fall in serum activity.
There was also a suggestion that patients
with metastatic disease had higher levels
than those with localized tumours and
long term follow-up studies showed that
raised lysozyme levels may occur as a
transient phenomenon in recurrent or
metastatic disease. They speculated that
the elevation of serum lysozyme activity
in these patients may reflect a host
reaction to the tumour. Subsequently
Jedrzejczak and Siekierzynski (1975) criti-
cized this series and stated that raised
serum lysozyme levels in cancer patients
may be due to increased granulocyte
turnover associated with infection and
are therefore of no diagnostic or prog-
nostic value. In the animal studies of
Currie and Eccles (1976) there was no
evidence of any infectious process, and
in the patients with malignant melanoma
and breast carcinoma, those with the
highest lysozyme levels were the patients
with primary lesions, none of which were
infected. Primary lesions in malignant
melanoma are frequently infiltrated with
macrophages (Currie, Lejeune and Fairley,
1971) and the production of increased
amounts of lysozyme is, I suggest, most
likely to be due to macrophages resident
in the tumour mass or in the regional
lymph nodes. Furthermore, single cell
suspensions obtained from human malig-
nant melanoma release lysozyme in vitro
in a manner similar to that found in the
rat tumours where it is associated with
the presence of macrophages.
There is an apparent contradiction
between the results obtained in the
animal model systems (Currie and Eccles,
1976) and those seen in the cancer
patients. In general, elevated lysozyme
levels in the cancer patients were asso-
ciated with early or localized disease
whereas in the HSBPA rat sarcoma, for
instance, the levels in the serum rose
progressively with tumour growth. How-
ever, the HSBPA tumour is highly
immunogenic, does not metastasize at
any stage and seems to maintain its
high content of macrophages throughout
tumour growth. The lysozyme data from
the cancer patients suggest that there
may be a fall in the macrophage content
of tumours as they grow and disseminate.
Our studies suggest that localized tumours
(malignant melanoma) have a higher
macrophage content than do distant
metastases. The rat sarcomata studied
in our previous paper (Currie and Eccles,
1976) present distinctly different types
of biological behaviour. The HSBPA
sarcoma already mentioned rarely meta-
stasizes and is associated with high
serum lysozyme levels, whereas the highly
metastatic tumour (MC3) evokes only low
serum levels. These rat sarcomata may
be analogues of the various stages in
the natural history of human " solid "
tumours. A localized primary tumour
is under some form of host restraint
associated with large numbers of macro-
phages resident within the tumour mass
and its draining regional lymph nodes.
This macrophage response could-account
for the elevated serum lysozyme levels.
The development of metastatic disease
due to (or accompanied by) the failure
of host resistance is associated with
sparse macrophage infiltration of the
tumour mass and therefore with lower
levels of lysozyme in the serum.
The serum level oflysozyme is affected
by many variables such as granulocyte
kinetics, renal function and the total
number of macrophages and monocytes
in the body. Because ofthis it is unlikely
to be of value as a screening test for
detecting or even following the progress
of cancer patients (Cooper et al., 1974).
However, in the presence of a histo-
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logically proven primary tumour it may be
of value in staging, by identifying those
patients in whom some form of host
resistance associated with macrophage
infiltration is still operating.
I am indebted to Dr Trevor Powles,
The Royal Marsden Hospital, for access
to the sera from patients with breast
carcinoma and to Isobel MacCallum for
expert technical assistance.
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